Related Experiment Video

Updated: Jul 6, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Inhibition of ICAM2 induces radiosensitization in oral squamous cell carcinoma cells

T Ishigami1, K Uzawa, K Fushimi

  • 1Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

British Journal of Cancer
|March 20, 2008
PubMed

Insights

Intercellular adhesion molecule 2 (ICAM2) promotes oral squamous cell carcinoma (OSCC) radioresistance. Silencing ICAM2 with small interfering RNA (siRNA) enhances radiosensitivity and antitumor effects in OSCC, suggesting ICAM2 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy Research

Background:

  • Oral squamous cell carcinoma (OSCC) exhibits radioresistance, a major challenge in radiotherapy.
  • Previous studies identified potential genes linked to OSCC radioresistance using gene expression profiling.

Purpose of the Study:

  • To investigate the role of intercellular adhesion molecule 2 (ICAM2) in OSCC radioresistance.
  • To evaluate the efficacy of combining ICAM2 small interfering RNA (siRNA) with X-ray irradiation for OSCC treatment.

Main Methods:

  • Utilized Affymetrix GeneChip for gene identification.
  • Employed small interfering RNA (siRNA) to downregulate ICAM2 expression in OSCC cells.
  • Assessed radiosensitivity, apoptosis (caspase-3 activation, AKT phosphorylation), and radioresistance phenotypes.
  • Investigated the effects of ICAM2 overexpression on radiosensitivity.

Main Results:

  • Downregulation of ICAM2 via siRNA significantly enhanced OSCC cell radiosensitivity.
  • ICAM2 silencing led to increased apoptosis, evidenced by caspase-3 activation and AKT phosphorylation (ser473).
  • Overexpression of ICAM2 conferred greater resistance to X-ray irradiation, demonstrating a radioresistance phenotype.

Conclusions:

  • ICAM2 plays a crucial role in mediating radioresistance in oral squamous cell carcinoma.
  • ICAM2 silencing enhances sensitivity to radiotherapy, indicating its potential as a therapeutic target.
  • Combination therapy of ICAM2 siRNA and X-ray irradiation shows promise for improving OSCC treatment outcomes.

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...